AEGLEA BIOTHERAPEUTICS INC.
1 day chart
Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its product candidate is Pegtarviliase, a novel polyethylene glycol modified (PEGylated), human enzyme engineered to reduce elevated levels of total homocysteine circulating in the plasma. It has engineered pegtarviliase by directed mutagenesis of amino acids within the wild-type human cystathionine y-lyase enzyme (CGL). The Company’s second product candidate Pegzilarginase is a PEGylated, recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance arginine-degrading activity of the enzyme in human plasma. The Company is engaged in advancing inflammatory bowel disease (IBD) portfolio which consists of SPY001 and SPY002, antibody candidates.
Buy US stocks in Australia starting with AGLE. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in AGLE
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.